Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expre… Read more
Arbutus Biopharma Corp (ABUS) - Net Assets
Latest net assets as of September 2025: $77.40 Million USD
Based on the latest financial reports, Arbutus Biopharma Corp (ABUS) has net assets worth $77.40 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($97.71 Million) and total liabilities ($20.31 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $77.40 Million |
| % of Total Assets | 79.21% |
| Annual Growth Rate | 7.62% |
| 5-Year Change | -4.51% |
| 10-Year Change | -82.22% |
| Growth Volatility | 2336.02 |
Arbutus Biopharma Corp - Net Assets Trend (1998–2024)
This chart illustrates how Arbutus Biopharma Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Arbutus Biopharma Corp (1998–2024)
The table below shows the annual net assets of Arbutus Biopharma Corp from 1998 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $97.37 Million | -8.16% |
| 2023-12-31 | $106.02 Million | -22.53% |
| 2022-12-31 | $136.85 Million | -19.23% |
| 2021-12-31 | $169.44 Million | +66.17% |
| 2020-12-31 | $101.97 Million | +40.17% |
| 2019-12-31 | $72.74 Million | -63.67% |
| 2018-12-31 | $200.23 Million | +9.72% |
| 2017-12-31 | $182.50 Million | -10.10% |
| 2016-12-31 | $203.00 Million | -62.93% |
| 2015-12-31 | $547.68 Million | +522.36% |
| 2014-12-31 | $88.00 Million | +48.67% |
| 2013-12-31 | $59.19 Million | +44.65% |
| 2012-12-31 | $40.92 Million | +686.08% |
| 2011-12-31 | $5.21 Million | -51.49% |
| 2010-12-31 | $10.73 Million | -69.72% |
| 2009-12-31 | $35.44 Million | -7.45% |
| 2008-12-31 | $38.29 Million | +108.43% |
| 2007-12-31 | $18.37 Million | +11711.55% |
| 2006-12-31 | $155.53K | +100.84% |
| 2005-12-31 | $-18.49 Million | -76.18% |
| 2004-12-31 | $-10.50 Million | -124.20% |
| 2003-12-31 | $43.38 Million | -4.34% |
| 2002-12-31 | $45.35 Million | -26.25% |
| 2001-12-31 | $61.49 Million | +104.76% |
| 2000-12-31 | $30.03 Million | +11.72% |
| 1999-12-31 | $26.88 Million | +86.28% |
| 1998-12-31 | $14.43 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arbutus Biopharma Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 132602488035.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.41 Billion | 1448.17% |
| Other Comprehensive Income | $-48.13 Million | -49.44% |
| Other Components | $82.05 Million | 84.27% |
| Total Equity | $97.37 Million | 100.00% |
Arbutus Biopharma Corp Competitors by Market Cap
The table below lists competitors of Arbutus Biopharma Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FirstSun Capital Bancorp Common Stock
OTCQX:FSUN
|
$543.11 Million |
|
Medincell SA
PA:MEDCL
|
$543.16 Million |
|
Shenzhen Lihexing Co. Ltd.
SHE:301013
|
$543.16 Million |
|
Shaanxi Heimao Coking Co Ltd
SHG:601015
|
$543.21 Million |
|
Shandong Jincheng Pharmaceutical and Chemical Co Ltd
SHE:300233
|
$542.91 Million |
|
Cosonic Intelligent Tech Co Ltd
SHE:300793
|
$542.89 Million |
|
Sumitomo Chemical India Limited
NSE:SUMICHEM
|
$542.75 Million |
|
Vitesse Energy Inc
NYSE:VTS
|
$542.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arbutus Biopharma Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 106,018,000 to 97,366,000, a change of -8,652,000 (-8.2%).
- Net loss of 69,920,000 reduced equity.
- New share issuances of 44,123,000 increased equity.
- Other comprehensive income increased equity by 286,000.
- Other factors increased equity by 16,859,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-69.92 Million | -71.81% |
| Share Issuances | $44.12 Million | +45.32% |
| Other Comprehensive Income | $286.00K | +0.29% |
| Other Changes | $16.86 Million | +17.32% |
| Total Change | $- | -8.16% |
Book Value vs Market Value Analysis
This analysis compares Arbutus Biopharma Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.31x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.65x to 8.31x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $6.67 | $4.36 | x |
| 1999-12-31 | $9.54 | $4.36 | x |
| 2000-12-31 | $6.09 | $4.36 | x |
| 2001-12-31 | $12.13 | $4.36 | x |
| 2002-12-31 | $6.90 | $4.36 | x |
| 2003-12-31 | $6.09 | $4.36 | x |
| 2004-12-31 | $-1.36 | $4.36 | x |
| 2005-12-31 | $-2.40 | $4.36 | x |
| 2006-12-31 | $0.04 | $4.36 | x |
| 2007-12-31 | $3.85 | $4.36 | x |
| 2008-12-31 | $4.72 | $4.36 | x |
| 2009-12-31 | $3.43 | $4.36 | x |
| 2010-12-31 | $1.04 | $4.36 | x |
| 2011-12-31 | $0.46 | $4.36 | x |
| 2012-12-31 | $2.86 | $4.36 | x |
| 2013-12-31 | $3.87 | $4.36 | x |
| 2014-12-31 | $3.92 | $4.36 | x |
| 2015-12-31 | $12.05 | $4.36 | x |
| 2016-12-31 | $3.83 | $4.36 | x |
| 2017-12-31 | $3.33 | $4.36 | x |
| 2018-12-31 | $3.62 | $4.36 | x |
| 2019-12-31 | $1.27 | $4.36 | x |
| 2020-12-31 | $1.34 | $4.36 | x |
| 2021-12-31 | $1.59 | $4.36 | x |
| 2022-12-31 | $0.91 | $4.36 | x |
| 2023-12-31 | $0.64 | $4.36 | x |
| 2024-12-31 | $0.52 | $4.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arbutus Biopharma Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -71.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1133.04%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.35x
- Recent ROE (-71.81%) is below the historical average (377.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -60.67% | -713.22% | 0.08x | 1.10x | $-10.20 Million |
| 1999 | -30.41% | -716.68% | 0.04x | 1.07x | $-10.86 Million |
| 2000 | -30.65% | -520.56% | 0.05x | 1.08x | $-12.21 Million |
| 2001 | -22.79% | -405.13% | 0.05x | 1.10x | $-20.16 Million |
| 2002 | -59.09% | -528.27% | 0.10x | 1.17x | $-31.33 Million |
| 2003 | -78.55% | -1247.26% | 0.05x | 1.17x | $-38.41 Million |
| 2004 | 0.00% | -230.49% | 0.30x | 0.00x | $-27.00 Million |
| 2005 | 0.00% | -60.64% | 0.72x | 0.00x | $-6.21 Million |
| 2006 | 11625.33% | 132.90% | 2.25x | 38.80x | $18.06 Million |
| 2007 | -14.06% | -16.22% | 0.64x | 1.35x | $-4.42 Million |
| 2008 | -30.60% | -121.56% | 0.23x | 1.11x | $-15.55 Million |
| 2009 | -26.32% | -67.68% | 0.33x | 1.18x | $-12.87 Million |
| 2010 | -115.68% | -58.14% | 1.02x | 1.96x | $-13.49 Million |
| 2011 | -186.95% | -59.69% | 1.19x | 2.63x | $-10.25 Million |
| 2012 | 73.18% | 211.19% | 0.27x | 1.29x | $25.86 Million |
| 2013 | -23.76% | -90.95% | 0.22x | 1.21x | $-19.98 Million |
| 2014 | -44.09% | -258.67% | 0.13x | 1.34x | $-47.60 Million |
| 2015 | -11.16% | -245.73% | 0.03x | 1.30x | $-115.89 Million |
| 2016 | -189.21% | -25606.67% | 0.01x | 1.36x | $-404.40 Million |
| 2017 | -46.25% | -788.79% | 0.05x | 1.30x | $-102.65 Million |
| 2018 | -28.52% | -967.80% | 0.03x | 1.14x | $-77.12 Million |
| 2019 | -211.32% | -2557.36% | 0.06x | 1.45x | $-161.00 Million |
| 2020 | -62.52% | -921.97% | 0.05x | 1.34x | $-73.94 Million |
| 2021 | -45.00% | -693.91% | 0.05x | 1.21x | $-93.19 Million |
| 2022 | -50.75% | -178.01% | 0.20x | 1.43x | $-83.14 Million |
| 2023 | -68.71% | -401.57% | 0.13x | 1.36x | $-83.45 Million |
| 2024 | -71.81% | -1133.04% | 0.05x | 1.35x | $-79.66 Million |
Industry Comparison
This section compares Arbutus Biopharma Corp's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $77.40 Million | -60.67% | 0.26x | $542.95 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |